Alto Neuroscience’s (ANRO) Outperform Rating Reaffirmed at William Blair

Alto Neuroscience (NYSE:ANRO)‘s stock had its “outperform” rating reaffirmed by stock analysts at William Blair in a report issued on Friday,RTT News reports.

Alto Neuroscience Price Performance

ANRO stock traded down $0.04 on Friday, hitting $2.65. 121,727 shares of the company were exchanged, compared to its average volume of 358,117. Alto Neuroscience has a twelve month low of $2.60 and a twelve month high of $18.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 13.09 and a current ratio of 13.10. The business’s fifty day moving average is $3.67 and its two-hundred day moving average is $6.22.

Alto Neuroscience (NYSE:ANRO) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.09. Analysts anticipate that Alto Neuroscience will post -2.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors and hedge funds have recently bought and sold shares of ANRO. Marshall Wace LLP acquired a new stake in shares of Alto Neuroscience in the fourth quarter worth $3,542,000. Point72 Asset Management L.P. increased its position in shares of Alto Neuroscience by 73.1% in the fourth quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company’s stock worth $7,158,000 after acquiring an additional 714,461 shares in the last quarter. Franklin Resources Inc. increased its position in shares of Alto Neuroscience by 95.3% in the third quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company’s stock worth $13,965,000 after acquiring an additional 595,673 shares in the last quarter. Woodline Partners LP increased its position in shares of Alto Neuroscience by 397.6% in the fourth quarter. Woodline Partners LP now owns 621,976 shares of the company’s stock worth $2,631,000 after acquiring an additional 496,976 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Alto Neuroscience by 198.1% in the fourth quarter. Northern Trust Corp now owns 587,135 shares of the company’s stock worth $2,484,000 after acquiring an additional 390,190 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.